Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Conference News ACC 2023

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Michael O'Riordan

March 13, 2023

News Conference News ACC 2023

MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis

Michael O'Riordan

March 10, 2023

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

Presentation ACC 2023

Complete Revascularization Strategies in Patients Presenting With Acute Coronary Syndrome and Multivessel Coronary Disease

Presenter: Roberto Diletti

March 05, 2023

News Conference News ACC 2023

STOP-CA: Atorvastatin Curbs Heart Function Decline During Chemotherapy

L.A. McKeown

March 04, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

News Conference News ACC 2022

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Michael O'Riordan

April 06, 2022

News Conference News ACC 2021

Global STEMI Initiative Helps Low- and Middle-Income Countries Achieve Better Metrics

L.A. McKeown

May 24, 2021

News Conference News ACC 2021

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Michael O'Riordan

May 18, 2021

News Conference News ACC 2021

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Michael O'Riordan

May 17, 2021

News Conference News ACC 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

L.A. McKeown

May 16, 2021

News Conference News ACC 2021

Poorer Neighborhoods Pose Risks for Black Patients After Acute MI

L.A. McKeown

May 05, 2021

News Conference News ACC 2020

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

Michael O'Riordan

March 30, 2020

News Conference News ACC 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

Shelley Wood

March 30, 2020

News Conference News ACC 2020

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

Caitlin E. Cox

March 28, 2020

Advertisement

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

MASTER@HEART: Long-term Endurance Athletes Not Immune to Atherosclerosis

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Complete Revascularization Strategies in Patients Presenting With Acute Coronary Syndrome and Multivessel Coronary Disease

STOP-CA: Atorvastatin Curbs Heart Function Decline During Chemotherapy

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Managing AF Patients Undergoing PCI—Some Lingering Questions

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Global STEMI Initiative Helps Low- and Middle-Income Countries Achieve Better Metrics

Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’

Apixaban Curbs Subclinical Thrombosis After TAVI in Patients Without Prior OAC

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

Poorer Neighborhoods Pose Risks for Black Patients After Acute MI

PCI Equal to Surgery in Left Main CAD: PRECOMBAT at 10 Years

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content